LDK378 (dihydrochloride)

Modify Date: 2024-01-08 17:06:06

LDK378 (dihydrochloride) Structure
LDK378 (dihydrochloride) structure
Common Name LDK378 (dihydrochloride)
CAS Number 1380575-43-8 Molecular Weight 631.057
Density N/A Boiling Point N/A
Molecular Formula C28H38Cl3N5O3S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of LDK378 (dihydrochloride)


Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.

 Names

Name 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine,dihydrochloride
Synonym More Synonyms

 LDK378 (dihydrochloride) Biological Activity

Description Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
Related Catalog
Target

IC50: 0.2 nM (ALK)[1].

In Vitro Ceritinib (LDK378) shows great anti-proliferative activity in Ba/F3-NPM-ALK and Karpas290 cells with IC50 of 26.0 nM and 22.8 nM, compared with IC50 of 319.5 nM and 2477 nM in Ba/F3-Tel-InsR and Ba/F3-WT cells[1].
In Vivo Ceritinib (LDK378) is designed to reduce the possibility of forming reactive metabolites and shows undetectable levels of glutathione (GSH) adducts (<1%) in liver microsomes. Ceritinib (LDK378) has relatively good metabolic stability, with moderate CYP3A4 (Midazolam substrate) inhibition and hERG inhibition. Ceritinib (LDK378) exhibits low plasma clearance in animals (mouse, rat, dog and monkey) compared to liver blood flow, with the oral bioavailability of above 55% in mouse, rat, dog and monkey. Ceritinib (LDK378) induces a dose-dependent growth inhibition and tumor regression in the Karpas299 and H2228 rat xenograft models, with no body-weight loss. Ceritinib (LDK378) shows no impact on insulin levels or plasma glucose utilization in the mouse upon chronic dosing up to 100 mg/kg[1].
References

[1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013, Jun 6.

 Chemical & Physical Properties

Molecular Formula C28H38Cl3N5O3S
Molecular Weight 631.057
Exact Mass 629.176086
PSA 116.85000
LogP 8.87040
Storage condition -20℃

 Synonyms

2,4-Pyrimidinediamine, 5-chloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-N-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-, hydrochloride (1:2)
5-Chloro-N-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine dihydrochloride
CS-1407
LDK378 dihydrochloride||LDK-378 dihydrochloride
LDK378 dihydrochloride
W-6134
LDK378 (dihydrochloride)